Company intelligence / Profile preview

NeuFluent

Seattle, Washington, United States

Ownership: Private
Development stage: Other

Overview

NeuFluent operates as a venture studio with FDA-cleared digital therapeutic technology (510(k) clearance received in 2024) that activates the vagus nerve while reducing sympathetic nervous system activation

Therapeutic areas: CardiovascularOtherPsychiatry
Modalities: DeviceDigital therapeuticsNeuroprostheticsGene therapy
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on NeuFluent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuFluent.

Explore the full profile